Actively Recruiting
Evaluating Oral NS-863 for Pulmonary Hypertension Linked to Interstitial Lung Disease A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Led by NS Pharma, Inc. · Updated on 2026-10-28
177
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the effectiveness and safety of NS-863, an oral drug, in adults with pulmonary hypertension associated with interstitial lung disease PH-ILD. The study focuses on participants with WHO Group 3 pulmonary hypertension confirmed by imaging and other diagnostic criteria. It aims to find the best dose of NS-863 while monitoring its impact on pulmonary vascular resistance and safety over 24 weeks. Participants will be randomly assigned to one of three groups low dose NS-863, high dose NS-863, or a matching placebo. The study drug is taken orally. The trial includes a treatment period lasting up to 24 weeks during which participants will be monitored closely for changes in lung and heart function, walking ability, breathlessness, and quality of life. Researchers will also assess various hemodynamic and echocardiographic parameters at 12 and 24 weeks. During the study, participants will attend scheduled visits for assessments including a 6-minute walk test, Borg dyspnea scale, echocardiograms, and questionnaires related to lung disease symptoms. Safety will be tracked by recording any adverse events throughout the trial duration. The main outcomes measured are changes from baseline to week 24 in pulmonary vascular resistance and safety events. Participants must be able to complete all visits and follow study instructions for the full duration of the trial.
CONDITIONS
Brief Title
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Research Team
T
Trial Info
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here